Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Gruenenthal Gmbh patents


Recent patent applications related to Gruenenthal Gmbh. Gruenenthal Gmbh is listed as an Agent/Assignee. Note: Gruenenthal Gmbh may have other listings under different names/spellings. We're not affiliated with Gruenenthal Gmbh, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "G" | Gruenenthal Gmbh-related inventors


 new patent  Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

A hitherto unknown crystalline form of (−)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. . ... Gruenenthal Gmbh

Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.. . ... Gruenenthal Gmbh

3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3 -diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

Treatment of irritable bowel syndrome

A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.. . ... Gruenenthal Gmbh

Semisolid aqueous pharmaceutical composition containing tapentadol

A semisolid aqueous pharmaceutical composition containing tapentadol or a physiologically acceptable salt thereof.. . ... Gruenenthal Gmbh

Stable formulation for parenteral administration of tapentadol

The invention relates to an aqueous pharmaceutical composition for parenteral administration comprising tapentadol or a physiologically acceptable salt thereof, wherein the concentration of tapentadol is within the range of from 0.10 to 8.00 mg/ml, based on the weight of tapentadol free base and based on the total volume of the composition; and wherein the ph value of the composition is buffered and within the range of from 4.0 to 6.0. The invention also relates to a container comprising the pharmaceutical composition and a process for the preparation thereof. ... Gruenenthal Gmbh

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n, n-dimethyl-4-phenyl-4',9' -dihydro-3'h-spiro[cyclohexane-1,1' -pyrano[3,4,b]indol]-4-amine and paracetamol or propacetamol

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro[cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient selected from paracetamol and propacetamol.. . ... Gruenenthal Gmbh

Stable formulation for parenteral administration of tapentadol

The invention relates to an an aqueous pharmaceutical composition for parenteral administration comprising tapentadol or a physiologically acceptable salt thereof; wherein the concentration of tapentadol is greater than 8.00 mg/ml, based on the weight of tapentadol free base and based on the total volume of the composition; wherein the composition comprises a buffer system; and wherein the ph value of the composition is within the range of from greater than 3.0 to less than 6.7. The invention also relates to a kit comprising the composition according to the invention in a packaging. ... Gruenenthal Gmbh

Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function

A hitherto unknown crystalline form of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. . The invention relates to cebranopadol or a physiologically acceptable salt thereof for use in the treatment or the prevention of pain and/or opioid drug dependence in a subject with impaired hepatic and/or renal function.. . ... Gruenenthal Gmbh

Pharmaceutical combination

A pharmaceutical combination comprising as components (a) at least one 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol compound, and (b) at least one nmda-antagonist, a pharmaceutical formulation and a dosage form comprising such a combination, and a method of treating pain, e.g. Inflammatory pain or neuropathic pain, in which components (a) and (b) are administered simultaneously or sequentially to a mammal, with component (a) being administered either before or after component (b), and with components (a) or (b) being administered to the mammal either via the same pathway of administration or via different pathways of administration.. ... Gruenenthal Gmbh

Use of 1-phenyl-3-dimethylaminopropane compounds for treating rheumatoid pain

The use of 1-phenyl-3-dimethylaminopropane compounds for the treatment of rheumatoid pain, especially rheumatoid arthritic pain, very especially preferably chronic rheumatoid arthritic pain.. . ... Gruenenthal Gmbh

Treatment of irritable bowel syndrome

A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.. . ... Gruenenthal Gmbh

Tapentadol compositions

The present invention provides a method of treating pain and pain related conditions by administering to a patient in need thereof, a therapeutically effective amount of a slow release tapentadol hydrochloride and therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (gaba) analogue. The present invention further provides a pharmaceutical composition comprising a therapeutically effective amount of a slow release tapentadol hydrochloride and a therapeutically effective amount of a second analgesic, wherein the second analgesic is gamma-aminobutyric acid (gaba) analogue.. ... Gruenenthal Gmbh

Substituted azaspiro(4.5)decane derivatives

The invention relates to substituted spirocyclic cyclohexane derivatives which have an affinity for the μ opioid receptor and/or the orl1 receptor, processes for the preparation thereof, medicaments containing these compounds and the use of these compounds for the preparation of medicaments.. . ... Gruenenthal Gmbh

07/13/17 / #20170197971

3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

07/13/17 / #20170197970

3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

07/13/17 / #20170197949

8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

07/13/17 / #20170197947

3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 3-((hetero-)aryl)-alkyl-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

07/13/17 / #20170197919

3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives

The invention relates to 3-(carboxyethyl)-8-amino-2-oxo-1,3-diazaspiro-[4.5]-decane derivatives, their preparation and their use in medicine, particularly in the treatment of pain.. . ... Gruenenthal Gmbh

07/13/17 / #20170196822

Use of tapentadol for inhibiting and/or treating depression and anxiety

The use of tapentadol (i) in the treatment of pain in a subject suffering from depression and/or from anxiety, and/or (ii) in the treatment or the inhibition of depression or anxiety.. . ... Gruenenthal Gmbh

06/15/17 / #20170166515

Crystalline forms of (-)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride

A hitherto unknown crystalline form of (−)-(1r,2r)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride, pharmaceutical compositions containing the new crystalline form, methods of producing the new crystalline form, and a related method of use including treatment of, e.g., pain and/or urinary incontinence.. . ... Gruenenthal Gmbh

05/11/17 / #20170128388

Pharmaceutical patch for transdermal administration of tapentadol

The invention relates to a pharmaceutical patch for transdermal administration of the pharmacologically active ingredient tapentadol or a physiologically acceptable salt thereof, the patch comprising a surface layer, an adhesive layer which comprises a pressure sensitive adhesive and at least a portion of the total amount of the pharmacologically active ingredient that is contained in the pharmaceutical patch, and a removable protective layer, wherein the adhesive layer is located between the surface layer and the removable protective layer.. . ... Gruenenthal Gmbh

03/30/17 / #20170087103

Prolonged release pharmaceutical composition containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol

A pharmaceutical formulation for prolonged release of the active ingredient 3-(3-dimethylamino-1-ethyl-2-methylpropyl)phenol or a pharmaceutically acceptable salt thereof in a matrix containing between 1 and 80 wt % of at least one pharmaceutically acceptable hydrophilic or hydrophobic polymer as a matrix forming agent and exhibiting in vivo the following release rate: 3 to 35% by weight (based on 100% by weight active ingredient) 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 0.5 hours; 5 to 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 1 hour; 10 to 75% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 2 hours; 15 to 82% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 3 hours; 30 to 97% by weight 3-(3-dimethylamino-1-ethyl-2-methyl -propyl)phenol released after 6 hours; more than 50% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 12 hours; more than 70% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 18 hours, and more than 80% by weight 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol released after 24 hours.. . ... Gruenenthal Gmbh

03/23/17 / #20170079938

Titration of tapentadol

The use of tapentadol for the manufacture of a medicament comprising at least one administration unit a containing dose a of tapentadol and at least one administration unit b containing dose b of tapentadol, where dose a<dose b, for the treatment of pain.. . ... Gruenenthal Gmbh

03/09/17 / #20170065560

Pharmaceutical composition comprising (1r,4r)-6'-fluoro-n,n-dimethyl-4-phenyl-4',9'-dihydro-3'h-spiro[cyclohexane-1,1'-pyrano[3,4,b]indo]-4-amine and antidepressants

The invention relates to a pharmaceutical composition comprising a first pharmacologically active ingredient selected from (1r,4r)-6′-fluoro-n,n-dimethyl-4-phenyl-4′,9′-dihydro-3′h-spiro [cyclohexane-1,1′-pyrano[3,4,b]indol]-4-amine and the physiologically acceptable salts thereof, and a second pharmacologically active ingredient which is an antidepressant.. . ... Gruenenthal Gmbh

03/02/17 / #20170056635

Device and formulation for topical treatment of pain affecting the vulvar area of the female human genital organ

The present invention relates to a device for the topical treatment of pain affecting the vulvar area of the female human genital organ, a formulation for use in the device according to the invention, and a kit comprising the device according to the present intention. Additionally, the present invention relates to a method of topical treatment of pain affecting the vulvar area of the female human genital organ, said method using the device according to the present invention. ... Gruenenthal Gmbh

02/16/17 / #20170042836

Treatment of irritable bowel syndrome

A method of treating irritable bowel syndrome in a patient in need thereof by administering to said patient a pharmaceutically effective amount of tapentadol.. . ... Gruenenthal Gmbh

02/02/17 / #20170027886

Abuse-proofed dosage forms

The invention relates to a form of administration which is secured against misuse and which is thermoformed without extrusion, comprising at least one synthetic or natural polymer having a resistance to breaking of at least 500 n in addition to one or several active ingredients with a misuse potential and, optionally physiologically compatible auxiliary substances. The invention also relates to a method for the production thereof.. ... Gruenenthal Gmbh








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Gruenenthal Gmbh in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Gruenenthal Gmbh with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###